Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MC1R | Q01726 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008064 | 0.87 | MC5R (0.70) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL25375854 | 0.87 | MC5R (0.47) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL8851504 | 0.85 | HPGD (0.61) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL20495649 | 0.83 | HPGD (0.69) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL29582547 | 0.83 | HPGD (0.69) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL9312714 | 0.82 | HPGD (0.58) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL8858591 | 0.81 | NQO2 (0.58) | HPGDCA2CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL9305839 | 0.81 | MC5R (0.58) | MC5RMAPK1MC1RHPGDMEN1 | |
| Hydrochloric Acid SCHEMBL17260184 | 0.80 | HPGD (0.56) | MC5RMAPK1MC1RHPGDMEN1 | |
| SCHEMBL20274550 | 0.80 | HPGD (0.56) | MC5RMAPK1MC1RHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | disclosed |
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-5200423-A | AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND FUNGICIDES CONTAINING THE SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1993-04-06 | — | — | US | disclosed |
| US-5106866-A | Skin disorders | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
| US-5021458-A | Amine derivatives and fungicides containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0164697-B1 | AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND FUNGICIDES CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| CN-1007975-B | Process for the preparation of amine derivatives | KAKEN PHARMACEUFICAL CO LTD (JP) | 1990-05-16 | — | — | CN | disclosed |
| CN-1035771-A | Process for the preparation of amine derivatives and fungicides containing amine derivatives | SCIENT RESEARCH AND PHARMACEUT (JP) | 1989-09-27 | — | — | CN | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
| CN-85104330-A | Process for the preparation of amine derivatives and fungicides containing amine derivatives | — | 1986-12-03 | — | — | CN | disclosed |
| EP-0164697-A2 | Amine derivatives, processes for preparing the same and fungicides containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | MC5R 553/4885MAPK1 3230/4885MC1R 581/4885 |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | MC5R 161/4885MAPK1 1641/4885MC1R 233/4885 |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | MC5R 124/4885MAPK1 412/4885MC1R 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.